JP2016523087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523087A5 JP2016523087A5 JP2016521893A JP2016521893A JP2016523087A5 JP 2016523087 A5 JP2016523087 A5 JP 2016523087A5 JP 2016521893 A JP2016521893 A JP 2016521893A JP 2016521893 A JP2016521893 A JP 2016521893A JP 2016523087 A5 JP2016523087 A5 JP 2016523087A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- compound according
- alkyl
- compound
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 262
- 239000002777 nucleoside Substances 0.000 claims description 92
- 125000005647 linker group Chemical group 0.000 claims description 89
- 108091034117 Oligonucleotide Proteins 0.000 claims description 77
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 48
- 125000003835 nucleoside group Chemical group 0.000 claims description 35
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 30
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 16
- 238000012986 modification Methods 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- -1 furanosyl nucleoside Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 150000004713 phosphodiesters Chemical class 0.000 claims description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- 229930024421 Adenine Chemical group 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 description 23
- 230000000692 anti-sense effect Effects 0.000 description 22
- 230000008685 targeting Effects 0.000 description 19
- 125000000217 alkyl group Chemical group 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 0 CCC(C(C)C1O)OCC1(NC(C)=O)OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@](*C(*)[C@](C)C1)C1NC(C)=O)=O)O)(COCCC(NCCCNC(CCCCO[C@@]1O*(C)C(*)C1NC(C)=O)=O)=O)NC(CCCC(NCCCCCCO[C@@]([C@@](*)OC1CONC)[C@@]1O)=O)=O)=O)=O Chemical compound CCC(C(C)C1O)OCC1(NC(C)=O)OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@](*C(*)[C@](C)C1)C1NC(C)=O)=O)O)(COCCC(NCCCNC(CCCCO[C@@]1O*(C)C(*)C1NC(C)=O)=O)=O)NC(CCCC(NCCCCCCO[C@@]([C@@](*)OC1CONC)[C@@]1O)=O)=O)=O)=O 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000764238 Isis Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000012739 integrated shape imaging system Methods 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 3
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical group CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838190P | 2013-06-21 | 2013-06-21 | |
| US61/838,190 | 2013-06-21 | ||
| US201361871683P | 2013-08-29 | 2013-08-29 | |
| US61/871,683 | 2013-08-29 | ||
| PCT/US2014/043731 WO2014205451A2 (en) | 2013-06-21 | 2014-06-23 | Compositions and methods for modulation of target nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029006A Division JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523087A JP2016523087A (ja) | 2016-08-08 |
| JP2016523087A5 true JP2016523087A5 (enExample) | 2017-08-03 |
| JP6694382B2 JP6694382B2 (ja) | 2020-05-13 |
Family
ID=52105553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521893A Active JP6694382B2 (ja) | 2013-06-21 | 2014-06-23 | 標的核酸を調節するための組成物および方法 |
| JP2020029006A Withdrawn JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020029006A Withdrawn JP2020099335A (ja) | 2013-06-21 | 2020-02-25 | 標的核酸を調節するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160122761A1 (enExample) |
| EP (3) | EP3011028B1 (enExample) |
| JP (2) | JP6694382B2 (enExample) |
| AU (2) | AU2014284152B2 (enExample) |
| CA (1) | CA2916252A1 (enExample) |
| WO (1) | WO2014205451A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| DK3019200T3 (da) * | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| CN110903337A (zh) | 2014-05-01 | 2020-03-24 | Ionis制药公司 | 用于调节生长激素受体表达的组合物和方法 |
| PE20170010A1 (es) * | 2014-05-01 | 2017-03-04 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion del factor b del complemento |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3151839A4 (en) * | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| KR20170068469A (ko) | 2014-10-10 | 2017-06-19 | 에프. 호프만-라 로슈 아게 | ＧａｌＮＡｃ 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도 |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| CA2999341A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
| DK4119569T3 (da) | 2015-11-06 | 2024-08-12 | Ionis Pharmaceuticals Inc | Konjugerede antisense-forbindelser til anvendelse i behandling |
| MA45478A (fr) | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| CN109661233A (zh) * | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN108239644B (zh) * | 2016-12-23 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| KR20250145702A (ko) | 2017-04-11 | 2025-10-13 | 아뷰터스 바이오파마 코포레이션 | 표적화 조성물 |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| KR102834361B1 (ko) | 2017-12-01 | 2025-07-17 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| JP7365052B2 (ja) * | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| JP2021533800A (ja) | 2018-08-21 | 2021-12-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用 |
| MX2021002745A (es) | 2018-09-11 | 2021-05-12 | Amgen Inc | Metodos de purificacion de oligonucleotidos ricos en guanina. |
| CN111655297A (zh) * | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| ES2932295T3 (es) * | 2018-11-13 | 2023-01-17 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresión de LPA en una célula |
| GB2579253A (en) * | 2018-11-28 | 2020-06-17 | Pedanius Therapeutics Ltd | Antibacterial antisense agents |
| KR20210102313A (ko) | 2018-12-10 | 2021-08-19 | 암젠 인크 | 화학적으로 변형된 RNAi 작제물 및 이의 용도 |
| CN113166761B (zh) | 2018-12-10 | 2025-09-09 | 美国安进公司 | 用于抑制pnpla3表达的rnai构建体 |
| US20220307022A1 (en) | 2019-05-30 | 2022-09-29 | Amgen Inc. | Rnai constructs for inhibiting scap expression and methods of use thereof |
| WO2020264055A1 (en) | 2019-06-25 | 2020-12-30 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
| AU2020329286A1 (en) | 2019-08-13 | 2022-03-17 | Amgen Inc. | RNAi constructs for inhibiting SLC30A8 expression and methods of use thereof |
| WO2021030778A1 (en) * | 2019-08-15 | 2021-02-18 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
| KR20220058578A (ko) | 2019-09-03 | 2022-05-09 | 아크투루스 쎄라퓨틱스, 인크. | 치료 활성 접합체의 아시알로당단백질 수용체 매개 전달 |
| JP7737667B2 (ja) * | 2019-09-18 | 2025-09-11 | 国立大学法人東京科学大学 | 核酸複合体 |
| AU2020399636A1 (en) | 2019-12-09 | 2022-06-02 | Amgen Inc. | RNAi constructs and methods for inhibiting LPA expression |
| WO2021194999A1 (en) | 2020-03-23 | 2021-09-30 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| KR20240004092A (ko) | 2020-06-01 | 2024-01-11 | 암젠 인크 | Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법 |
| CN116194119A (zh) | 2020-08-13 | 2023-05-30 | 美国安进公司 | 用于抑制MARC1表达的RNAi构建体和方法 |
| JP2023546199A (ja) * | 2020-10-20 | 2023-11-01 | サノフイ | アシアロ糖タンパク質受容体のための新規リガンド |
| MX2023005198A (es) | 2020-11-05 | 2023-05-16 | Amgen Inc | Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa. |
| JP2024504505A (ja) | 2021-01-30 | 2024-01-31 | イー セラピューティクス パブリック リミテッド カンパニー | コンジュゲートオリゴヌクレオチド化合物、その作製方法及び使用 |
| CA3204317A1 (en) * | 2021-01-30 | 2022-08-04 | Ahmad Ali MORTAZAVI | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| WO2022162161A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| CN114716490B (zh) * | 2021-03-08 | 2022-11-25 | 南京吉迈生物技术有限公司 | GalNAc簇亚磷酰胺和靶向治疗性核苷 |
| WO2022246195A1 (en) * | 2021-05-20 | 2022-11-24 | Olix Us, Inc. | Functional moieties and their uses and synthetic preparation |
| AR127184A1 (es) | 2021-09-30 | 2023-12-27 | Amgen Inc | Métodos de separación de especies moleculares de oligonucleótidos ricos en guanina |
| WO2023059629A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
| MX2024004913A (es) | 2021-10-22 | 2024-05-06 | Amgen Inc | Constructos de arni para inhibir la expresion de gpam y metodos de uso de los mismos. |
| TW202330920A (zh) | 2021-12-01 | 2023-08-01 | 美商戴瑟納製藥股份有限公司 | 用於調節ａｐｏｃ３表現之組合物及方法 |
| IL314394A (en) | 2022-02-25 | 2024-09-01 | Amgen Inc | Methods for preparing high-concentration liquid drug substances |
| PE20250754A1 (es) | 2022-07-25 | 2025-03-13 | Amgen Inc | Construcciones de arni y metodos para inhibir la expresion de fam13a |
| IL321194A (en) | 2022-12-16 | 2025-07-01 | Amgen Inc | RNA interference constructs for inhibiting TTR expression and methods for using them |
| US20250243487A1 (en) * | 2023-09-14 | 2025-07-31 | Ionis Pharmaceuticals, Inc. | Compounds and Methods for Reducing APOCIII Expression |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US23861A (en) * | 1859-05-03 | Improvement in revolving fire-arms | ||
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| DE3851889T2 (de) | 1987-06-24 | 1995-04-13 | Florey Howard Inst | Nukleosid-derivate. |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| CA2088258C (en) | 1990-07-27 | 2004-09-14 | Phillip Dan Cook | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| CA2122365C (en) | 1991-11-26 | 2010-05-11 | Brian Froehler | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| EP0626387B1 (de) | 1993-05-12 | 1999-03-10 | Novartis AG | Nukleoside und Oligonukleotide mit 2'-Ethergruppen |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| EP0862439A4 (en) | 1995-11-22 | 2001-01-10 | O Paul O P Ts | LIGANDS FOR INCREASING THE CELLULAR UPtake OF BIOMOLECULES |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| PT1178999E (pt) | 1999-05-04 | 2007-06-26 | Santaris Pharma As | Análogos de l-ribo-lna |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
| EP1560840B1 (en) | 2002-11-05 | 2015-05-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | Ｎ−ｏ結合性架橋構造型新規人工核酸 |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| US20090203132A1 (en) | 2004-09-09 | 2009-08-13 | Swayze Eric E | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
| US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| EP3705125B1 (en) | 2007-12-04 | 2023-07-05 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AU2009234266B2 (en) | 2008-04-11 | 2015-08-06 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2009143369A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Method of preparing nucleosides and analogs thereof without using chromatography |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US8883752B2 (en) | 2008-10-24 | 2014-11-11 | Isis Pharmaceuticals, Inc. | 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| WO2010083615A1 (en) * | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
| WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP3173419A1 (en) * | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
| EP2616543A1 (en) | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
| WO2012067970A2 (en) * | 2010-11-11 | 2012-05-24 | Ted M Dawson | Transcriptional repression leading to parkinson's disease |
| KR20190062511A (ko) | 2011-04-27 | 2019-06-05 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정 |
| MX344807B (es) * | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3). |
| US9976138B2 (en) * | 2011-08-29 | 2018-05-22 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| CA3170716A1 (en) | 2013-02-14 | 2014-08-21 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2014
- 2014-06-23 AU AU2014284152A patent/AU2014284152B2/en active Active
- 2014-06-23 EP EP14813192.3A patent/EP3011028B1/en active Active
- 2014-06-23 CA CA2916252A patent/CA2916252A1/en not_active Abandoned
- 2014-06-23 US US14/898,873 patent/US20160122761A1/en not_active Abandoned
- 2014-06-23 EP EP20173519.8A patent/EP3730619A1/en not_active Withdrawn
- 2014-06-23 EP EP19179457.7A patent/EP3564374A1/en not_active Withdrawn
- 2014-06-23 JP JP2016521893A patent/JP6694382B2/ja active Active
- 2014-06-23 WO PCT/US2014/043731 patent/WO2014205451A2/en not_active Ceased
-
2018
- 2018-11-05 US US16/181,206 patent/US20190127737A1/en not_active Abandoned
-
2019
- 2019-12-23 AU AU2019284048A patent/AU2019284048A1/en not_active Withdrawn
-
2020
- 2020-02-25 JP JP2020029006A patent/JP2020099335A/ja not_active Withdrawn
- 2020-03-09 US US16/813,241 patent/US20200270609A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523087A5 (enExample) | ||
| JP7008056B2 (ja) | 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ | |
| JP6884250B2 (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP2022036182A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP7317029B2 (ja) | 修飾化合物及びその使用 | |
| US10041074B2 (en) | Euchromatic region targeting methods for modulating gene expression | |
| AU2021203174A1 (en) | Compositions and methods for modulating RNA | |
| US10758558B2 (en) | Hybrid oligonucleotides and uses thereof | |
| JP2019503394A5 (enExample) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP6326433B2 (ja) | 三環式ヌクレオシド及びそれから調製されるオリゴマー化合物 | |
| JP2015504650A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2018507711A5 (enExample) | ||
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста | |
| JP2009532044A5 (enExample) | ||
| JP7138349B2 (ja) | 核酸化合物およびオリゴヌクレオチド | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2018518167A5 (enExample) | ||
| JPWO2019175260A5 (enExample) | ||
| HRP20210139T1 (hr) | Sastavi i postupci za korigiranje mišične distrofije donjih udova tipa 2c upotrebom preskakanja egzona | |
| JP2022521510A (ja) | ホスホノアセテートギャップマー型オリゴヌクレオチド |